Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:administrativeDivision |
every 3 weeks
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinicalTrials |
Phase 1
oncology Phase 2 Phase 3 KEYNOTE-001 KEYNOTE-002 KEYNOTE-006 KEYNOTE-024 KEYNOTE-048 KEYNOTE-407 KEYNOTE-716 KEYNOTE-775 KEYNOTE-789 KEYNOTE-811 KEYNOTE-189 KEYNOTE-010 KEYNOTE-522 KEYNOTE-585 KEYNOTE-598 KEYNOTE-703 |
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:dosageForm |
solution for infusion
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pembrolizumab
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2014
|
| gptkbp:launchSite |
vein
|
| gptkbp:mandates |
advanced cancer
|
| gptkbp:marketedAs |
Keytruda
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchAreas |
cancer treatment
immunotherapy |
| gptkbp:route |
IV
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea rash immune-mediated reactions pruritus |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
PD-1
|
| gptkbp:triggerType |
PD-1 inhibitor
|
| gptkbp:usedFor |
treatment of melanoma
treatment of Hodgkin lymphoma treatment of bladder cancer treatment of non-small cell lung cancer treatment of head and neck squamous cell carcinoma |
| gptkbp:variant |
radiation therapy
chemotherapy |